혈당 측정기 시장 : 제품별, 기술별, 유통 채널별, 지역별(2024-2031년)

Glucometer Market Valuation - 2024-2031

Enhance access to diabetes care and management instruments, such as glucometers, via subsidies, insurance coverage, and public health programmes, are critical drivers of market expansion. According to the analyst from Verified Market Research, the Glucometer Market is estimated to reach a valuation of USD 24.38 Billion over the forecast period 2031, by subjugating around USD 10.68 Billion valued in 2024.

The global increase in diabetes cases, caused by factors such as ageing populations, sedentary lifestyles, and rising obesity rates, is significantly driving up demand for glucometers. It enables the market to grow at a CAGR of 10.87% from 2024 to 2031.

Glucometer Market: Definition/ Overview

A glucometer, also known as a blood glucose meter, is a portable medical device designed to measure and monitor the concentration of glucose in a person's blood. Primarily used by individuals with diabetes, glucometers play a crucial role in managing blood glucose levels, which is essential for effective diabetes control. The device typically consists of a small handheld unit with a digital display, along with a lancet for pricking the skin to obtain a blood sample. Users place a drop of blood on a disposable test strip, which is then inserted into the glucometer.

Glucometer analyzes the blood sample and provides a numerical reading of the blood glucose level, usually expressed in milligrams per deciliter (mg/dL) or millimoles per liter (mmol/L). Regular monitoring with a glucometer enables individuals to make informed decisions about their diet, medication, and lifestyle, ultimately helping to maintain optimal blood sugar control and reduce the risk of diabetes-related complications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How does the Increasing Prevalence of Diabetes Influence the Growth of the Glucometer Market?

The increasing prevalence of diabetes significantly influences the growth of the glucometer market by creating a larger demand for effective blood glucose monitoring solutions. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a figure projected to rise to 643 million by 2030 and further to 783 million by 2045. This escalating number of diabetes cases highlights the urgent need for glucometers, as regular monitoring is crucial for managing blood sugar levels and preventing complications associated with the disease.

Moreover, the growing awareness of diabetes management and the importance of self-monitoring practices, supported by government initiatives, further drive market demand. In 2021 alone, diabetes was responsible for approximately 6.7 million deaths worldwide, emphasizing the critical need for accessible monitoring tools.

Additionally, advancements in technology, such as the development of continuous glucose monitoring systems, are making these devices more user-friendly and appealing, further contributing to market expansion.

What are the Main Technological Challenges Faced by Manufacturers in the Glucometer Market?

Manufacturers in the glucometer market face several technological challenges that impact their ability to innovate and meet growing consumer demands. One of the primary challenges is the need for enhanced accuracy and reliability in glucose measurements. Despite advancements, discrepancies between glucometer readings and actual blood glucose levels can occur, leading to potential mismanagement of diabetes. According to the International Diabetes Federation, diabetes resulted in approximately 6.7 million deaths in 2021, underscoring the critical need for precise monitoring tools to prevent such outcomes.

Additionally, regulatory compliance poses a significant hurdle. Glucometers are classified as medical devices, which means they must adhere to stringent regulations set forth by authorities like the U.S. Food and Drug Administration (FDA). This compliance process can be time-consuming and costly, often delaying product launches and innovations. Another challenge is the competition from alternative monitoring methods, such as continuous glucose monitoring (CGM) systems, which provide real-time data without the need for frequent finger pricking. As CGM technology gains popularity, traditional glucometer manufacturers must invest in research and development to enhance their offerings and retain market share.

Furthermore, the high cost of advanced glucometer technologies can limit accessibility, particularly in low- and middle-income countries where diabetes prevalence is rising. The combination of these technological challenges requires manufacturers to continuously innovate while navigating regulatory landscapes and addressing market competition to ensure the effective management of diabetes.

Category-Wise Acumens

What Factors Contribute to the Dominance of Self-monitoring Blood Glucose (SMBG) Systems in the Glucometer Market?

The dominance of self-monitoring blood glucose (SMBG) systems in the glucometer market can be attributed to several key factors. Firstly, the rising prevalence of diabetes significantly drives demand for these devices. According to the Centers for Disease Control and Prevention (CDC), approximately 11.6% of the U.S. population, equating to about 38.4 million individuals, were affected by diabetes in 2021. This growing patient base necessitates effective monitoring solutions to manage blood glucose levels effectively and prevent complications associated with the disease.

Additionally, advancements in technology have made SMBG systems more accurate, user-friendly, and accessible. Features such as Bluetooth connectivity, integration with mobile health applications, and improved test strip designs enhance the overall user experience, encouraging more individuals to engage in regular monitoring. Furthermore, supportive government initiatives and reimbursement policies for SMBG devices in many regions promote their adoption, making them more financially accessible to patients.

The shift towards home-based healthcare, accelerated by the COVID-19 pandemic, has also bolstered the SMBG market, as patients increasingly prefer the convenience of monitoring their blood glucose levels at home rather than frequent hospital visits.

How does the Cost-Effectiveness of Invasive Glucometers Contribute to their Market Dominance?

The cost-effectiveness of invasive glucometers significantly contributes to their dominance in the glucometer market by making them accessible to a broader range of consumers, particularly those managing diabetes. Invasive glucometers, which typically involve finger-pricking to obtain blood samples, are regarded as the gold standard for blood glucose monitoring due to their accuracy and reliability. The American Diabetes Association and the International Diabetes Federation recommend these devices for effective diabetes management, reinforcing their credibility among healthcare providers and patients alike.

Government statistics further highlight the importance of cost-effectiveness in this market. For instance, the Centers for Disease Control and Prevention (CDC) reported that approximately 11.6% of the U.S. population, or about 38.4 million individuals, were living with diabetes in 2021. As the demand for affordable and reliable monitoring solutions rises, invasive glucometers remain a preferred choice due to their relatively low initial costs compared to newer technologies like continuous glucose monitoring systems.

Moreover, the widespread availability of test strips and lancets, which are essential consumables for invasive glucometers, helps maintain their affordability. The combination of these factors ensures that invasive glucometers continue to dominate the market, as they provide a cost-effective solution for millions of individuals needing regular blood glucose monitoring to manage their diabetes effectively.

Country/Region-wise Acumens

What Factors are Driving Asia Pacific's Dominance in the Glucometer Market?

Asia Pacific's dominance in the glucometer market is driven by several key factors, primarily the rising prevalence of diabetes and increasing healthcare investments. The International Diabetes Federation reported that over 206 million adults in the Asia Pacific region were living with diabetes in 2021, a number projected to rise to 238 million by 2030. This alarming trend necessitates effective blood glucose monitoring solutions, leading to heightened demand for glucometers.

Additionally, the region has seen significant government initiatives aimed at improving diabetes management and healthcare infrastructure. Furthermore, increasing awareness about diabetes and its management among patients and healthcare providers is driving the adoption of self-monitoring blood glucose devices. The accessibility of advanced technologies, such as continuous glucose monitoring systems, is also enhancing the market landscape. Collectively, these factors position Asia Pacific as a rapidly expanding market for glucometers, with a strong outlook for continued growth in the coming years.

What Factors are Driving the Continuous Growth of the Glucometer Market in North America?

The glucometer market in North America is experiencing continuous growth driven by several key factors. One of the primary drivers is the increasing prevalence of diabetes in the region. According to the Centers for Disease Control and Prevention (CDC), approximately 37.3 million people in the United States had diabetes in 2021, representing 11.3% of the population. This alarming statistic highlights the urgent need for effective blood glucose monitoring solutions, which is fueling the demand for glucometers.

Technological advancements in glucometer design and functionality are also driving the market's expansion. The development of compact, user-friendly devices with improved accuracy and connectivity features, such as Bluetooth integration and mobile app integration, is making glucometers more appealing to patients and healthcare providers alike. These innovations are enhancing the overall user experience and encouraging more individuals to engage in regular blood glucose monitoring.

Furthermore, the growing awareness of the importance of diabetes management and the availability of educational resources are contributing to the market's growth. As patients and healthcare providers become more informed about the significance of regular blood glucose monitoring in preventing complications and improving overall health outcomes, the demand for glucometers is expected to continue rising.

Competitive Landscape

The Glucometer Market is characterized by fierce competition among participants, which is driven by technological advancements, accuracy, and user-friendliness. Other essential variables that organizations consider while establishing and maintaining their market presence include price competitiveness, product differentiation, and worldwide expansion.

Some of the prominent players operating in the glucometer market include:

Abbott Diabetes Care

Roche Diagnostics

Medtronic

Dexcom

LifeScan

Ascensia Diabetes Care

Ypsomed

Braun

Nipro

Sanofi

Arkray

Prodigy Diabetes Care

Acon Laboratories

Nova Biomedical

Terumo

Latest Developments

In October 2023, Abbott launched the FreeStyle Libre 3 system in Canada, which is designed to provide real-time glucose readings with a smaller, more discreet sensor that offers improved accuracy and comfort for users.

In September 2023, Roche launched the Accu-Chek Instant, a new glucometer designed to provide users with instant feedback on their blood glucose levels. This device features a user-friendly interface and offers advanced connectivity options, allowing users to track their glucose levels more efficiently through a mobile app.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL GLUCOMETER MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL GLUCOMETER MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis
• 4.5 Regulatory Framework

5 GLOBAL GLUCOMETER MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Continuous Glucose Monitoring Devices
• 5.3 Self-Monitoring Blood Glucose (SMBG) Systems

6 GLOBAL GLUCOMETER MARKET, BY TECHNIQUE

• 6.1 Overview
• 6.2 Invasive
• 6.3 Non-invasive

7 GLOBAL GLUCOMETER MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospital Pharmacies
• 7.3 Retail Pharmacies
• 7.4 Online Pharmacies
• 7.5 Others

8 GLOBAL GLUCOMETER MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East and Africa

9 GLOBAL GLUCOMETER MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Share
• 9.3 Vendor Landscape
• 9.4 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Abbott Diabetes Care
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Roche Diagnostics
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Medtronic
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Dexcom
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 LifeScan
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Ascensia Diabetes Care
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Ypsomed
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 B. Braun
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Nipro
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Sanofi
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports